1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Ok Biotech Co., Ltd.

Ok Biotech Co., Ltd.

TTWSE:4155
16.80
TWD
-0.40
(-2.33%)
1.84EPS
9.57P/E
2.28BMarket Cap
Nov 17Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
19.44
8.77
11.48
13.95
16.26
12.9
14.95
15.83
11.85
14.13
9.3
11.7
10.95
11.14
Basic EPS, GAAP
2.5
0.99
1.49
1.14
1.67
1.86
1.51
1.38
0.41
1.37
0.02
0.66
0.58
1.76
Free Cash Flow per Basic Share
-2.1
-0.54
2.72
2.73
0.13
0.88
-0.39
0.72
-0.61
-0.51
-3.39
-2.16
-0.58
1.88
Dividend per Share
0.18
0.22
0.14
1.34
1.32
1.28
2
1.2
1.24
0.9
1.13
0.31
0.31
- -
Book Value per Share
10.41
12.34
12.25
12.3
13.99
14.62
14.45
16.37
16.14
16.44
16.45
16.95
17.81
18.51
Tangible Book Value per Share
10.4
12.34
12.25
12.3
13.99
14.27
13.77
15.87
15.71
16.15
16.28
13.69
14.51
15.14
Basic Weighted Avg Shares
55
72
75
75
76
87
83
94
107
105
128
143
142
138
Sales/Revenue/Turnover
1,074
634
857
1,040
1,233
1,120
1,241
1,484
1,263
1,484
1,192
1,670
1,556
1,537
Operating Margin (%)
13.13
6.07
13.22
10.38
10.59
12.65
8.78
8.65
0.78
9.45
0.15
2.42
7.66
11.01
Depreciation Expense
22
29
29
26
23
30
41
50
56
68
76
72
94
92
Net Income, GAAP
138
71
111
85
127
161
126
130
43
143
3
94
82
242
Effective Tax Rate (%)
11.32
9.75
22.94
35.74
22.3
20.38
21.41
20.01
31.9
22.14
119.86
16.36
6.49
11.92
Profit Margin (%)
12.86
11.26
12.96
8.19
10.28
14.4
10.13
8.74
3.44
9.67
0.25
5.63
5.3
15.76
Working Capital
10
215
304
253
404
472
438
622
788
698
739
728
702
802
LT Debt
227
211
249
232
195
256
288
128
402
386
94
356
697
819
Total Equity
610
849
950
945
1,206
1,264
1,302
1,739
1,703
1,846
2,395
2,567
2,576
2,574
Return on Invested Capital (%)
14.12
2.76
6.8
5.58
7.16
6.96
5.17
5.46
0.43
3.53
0.04
1.57
2.89
5.54
Return on Capital (%)
16.47
6.37
9.08
7.07
9.19
10.69
8.55
7.19
2.64
6.28
0.21
2.86
2.24
6.72
Return on Common Equity (%)
26.05
9.78
12.33
8.99
11.79
13.15
9.91
8.59
2.53
8.08
0.14
3.84
3.29
9.9

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
337
263
225
LT Borrowings
606
679
737
LT Finance Leases
91
79
82
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
141
141
136
Market Capitalization
2,283
2,063
2,283

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,249
1,272
1,374
Cash, Cash Equivalents & STI
327
318
383
Accounts Receivable, Net
381
444
476
Inventories
456
445
445
Total Current Liabilities
548
511
573
Payables & Accruals
- -
- -
- -
ST Debt
337
263
225
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.21%
8.72%
0.36%
Free Cash Flow
53.56%
78.8%
-73.46%
Net Income, GAAP
317.51%
628.23%
-12.26%
Sales/Revenue/Turnover
7.74%
3.24%
-6.81%
Total Cash Common Dividend
84.41%
-5.66%
-0.75%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
352
439
458
421
1,670
2025
412
427
380
338
1,556
2026
384
436
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.25
0.29
-0.17
0.31
0.66
2025
0.17
-0.57
0.6
0.42
0.58
2026
0.39
0.34
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.31
2025
- -
- -
- -
- -
0.31
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chia Te Lai
Full Time Employees
62
Sector
Health technology
Industry
Medical specialties
Address
No. 91, Gongdao 5th Road Hsinchu HSZ Taiwan 30070
IPO Date
Dec 30, 2010
Website
okbiotech.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
OK Biotech Co., Ltd. (4155.TW) develops, manufactures, markets and sells blood glucose monitoring systems and home healthcare devices. Founded in 2004 and headquartered in Hsinchu City, Taiwan, the company offers glucometers and blood glucose test strips under its OKB brand and U.S. subsidiary Prodigy brand; nebulizers including portable nebulizers, mesh nebulizers and related test strips; OTC hearing aids; and personal sound amplifiers, with professional OEM/ODM customized services. Products hold approvals including U.S. FDA 510(k), EU CE0123, Brazil Anvisa and China SFDA, and are distributed in over 60 countries across five continents, primarily targeting diabetes patients, hospitals, clinics and home users in the Americas, Taiwan, Asia and other regions. OK Biotech maintains ISO 13485 and QMS certifications at its automated production facilities and advanced quality labs, emphasizing R&D in glucose monitoring algorithms and hearing aid processing. The company listed on the Taiwan Stock Exchange in 2010 and continues global expansion through its logistics and after-sales network without reported major acquisitions, funding rounds, partnerships or strategic shifts in the last 1-2 years.